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Abstract
Purpose The incidence of invasive fungal disease (IFD) is
rising, but its treatment in paediatric haematology and oncol-
ogy patients is not yet standardised. This review aimed to
critically appraise and analyse the clinical practice guidelines
(CPGs) that are available for paediatric IFD.
Methods Electronic searches of MEDLINE, MEDLINE in-
Process & Other non-Indexed Citations, the Guidelines
International Network (GIN), guideline.gov and Google
were performed and combined fungal disease (Fung* OR
antifung*OR Candida* OR Aspergill*) with prophylaxis or
treatment (prophyl* OR therap* OR treatment). All guidelines
were assessed using the AGREE II tool and recommendations
relating to prophylaxis, empirical treatment and specific
therapy were extracted.
Results Nineteen guidelines met the inclusion criteria. The
AGREE II scores for the rigour of development domain
ranged from 11 to 92 % with a median of 53 % (interquartile
range 32–69%). Fluconazole was recommended as antifungal
prophylaxis in all nine of the included guidelines which rec-
ommended a specific drug. Liposomal amphotericin B was
recommended in all five guidelines giving empirical therapy
recommendations. Specific therapy recommendations were
given for oral or genital candidiasis, invasive candida infec-
tion, invasive aspergillosis and other mould infections.
Conclusions In many areas, recommendations were clear
about appropriate practice but further clarity was required,
particularly relating to the decision to discontinue empirical
antifungal treatment, the relative benefits of empiric and pre-
emptive strategies and risk stratification.
Future CPGs could consider working to published guide-
line production methodologies and sharing summaries of ev-
idence appraisal to reduce duplication of effort, improving the
quality and efficiency of CPGs in this area.
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Background
Invasive fungal disease (IFD) describes tissue damage associ-
ated with clinical illness as a result of infection with yeast or
mould. The incidence of IFD is rising, perhaps related to more
intensive immunosuppression in the treatment of patients with
a variety of conditions as well as improved survival of those
with inherited immunodeficiencies [1]. Meanwhile, deaths
due to IFD in the USA rose from 0.13 to 0.21 per 100,000
population in 0–4 year olds and from 0.13 to 0.31 per 100,000
population in 5–24 year olds between 1980 and 1997 [1].
Within paediatrics, the patients most commonly affected by
IFD are those with haematological malignancy (particularly
acute myeloid leukaemia and relapsed acute lymphoblastic
leukaemia), those undergoing allogeneic haematopoietic stem
cell transplant (HSCT) and those receiving highly myelosup-
pressive chemotherapy for other malignancies [2]. The out-
come of IFD with current therapies is poor. Yeast infections,
including Candida, are associated with mortality of 10–50 %.
Invasive Aspergillus is even more challenging with 52.5–
85 % mortality [3–5].
The treatment of IFD is not yet standardised. A recent
review of practice in multiple clinical centres found that the
prophylactic therapy administered for paediatric IFD varies
widely [6]. This may be due, in part, to regional variations
in the epidemiology of IFD resulting in different antifungal
susceptibility patterns. However, it may also be related to
minimal available trial data on the use of antifungal agents
in paediatric patients leading to the extrapolation of outcomes
from adult studies. For this reason, the pharmacokinetic and
pharmacodynamic properties of many antifungal agents in
children are undefined. Furthermore, the spectrum of antifun-
gal coverage, side effect profile, and interactions with other
medications varies, which results in no clear choice of first-
line antifungal treatment [7].
Given these treatment challenges in paediatric IFD, institu-
tions have created clinical practice guidelines (CPGs) to help
physiciansmanage this group of patients. CPGs are statements
compiled following a systematic search of the evidence to
assist healthcare practitioners in making decisions about indi-
vidual patients based on the best available research combined
with clinical expertise. Through systematic research and de-
velopment, a core of key principles have been derived which
delineate high-quality guidelines, leading to guideline creation
manuals from the National Institute for Health and Clinical
Excellence (NICE) in England and Wales, the US Institute of
Medicine (IOM) and the Scottish Intercollegiate Guidelines
Network (SIGN).
We anticipated that some guidelines included in this review
might have been less thorough in their approach to systemat-
ically reviewing the literature and compiling the evidence to
support their recommendations. Thus, although we use the
acronym CPGs throughout this review, readers should note
that some guidelines may not fully meet the stringent criteria
of an ideal CPG. The assessment of the recommendation pro-
duction process and the quality of guidelines was felt to be an
essential part of this review and informs the results and con-
clusions drawn.
The AGREE II tool is an appraisal tool developed to assess
the quality of guidelines and consists of 23 items [8]. The
items are grouped within six domains to provide key areas
for guideline development. These domains are scope and pur-
pose, stakeholder involvement, rigour of development, clarity
of presentation, applicability, and editorial independence.
Guidelines should be scored on each item by independent
assessors using a seven-point Likert scale where 1 represents
a poor score and 7 represents excellent demonstration of key
quality criteria. The item scores are then combined to give
scaled domain scores in percentages. Assessors are also re-
quested to provide an opinion on whether they would recom-
mend the assessed guideline for clinical use. The AGREE II
tool, and further information on its development and applica-
tion, is available from www.agreetrust.org. An overview of
the items and domains is given within Table 1.
This review aimed to examine the clinical practice guide-
lines (CPGs) that are available for paediatric IFD. It aimed to
assess the quality of guidance available to paediatric
haematology and oncology teams. From this, we aimed to
determine whether resources should be directed towards de-
veloping new or improved guidance or on the implementation
of CPGs that are already in circulation.
Methods
Searches
A protocol for the reviewwas developed prior to commencing
the work. Electronic searches of MEDLINE, MEDLINE in-
Process & Other non-Indexed Citations, the Guidelines
International Network (GIN), guideline.gov and Google
(first 200 Google results only) were performed in September
2013, combining fungal disease (Fung* OR antifung*OR
Candida* OR Aspergill*) with prophylaxis or treatment
(prophyl* OR therap* OR treatment). Within MEDLINE,
searches were limited to ‘Guideline’ within the Article Type.
Experts in the field were contacted asking for further potential
guidelines. An updated search was performed in September
2015.
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Inclusion
Guidelines regarding antifungal prophylaxis or treatment of
established fungal infection or both were included. A decision
was made not to include a reference to paediatrics within the
search criteria as it was recognised that many paediatric guide-
lines could be embedded within adult guidelines. When
screening for inclusion to this review, only those guidelines
with explicit recommendations for paediatric patients were
included. Furthermore, no search criteria relating to
haematology, oncology or malignancy was included as guide-
lines for these patients may be included within more general-
ised guidelines about antifungal therapies. Only those guide-
lines which explicitly state that they are intended for use in
patients with haematological and oncological diagnoses were
included in this review. Only guidelines with acknowledge-
ment from a producing body which had been published for-
mally or deposited in an accredited repository were consid-
ered. Only English language guidelines were included. No
date limitations were applied. The most up-to-date published
version of each guideline was included.
Study selection
One researcher reviewed all titles for those clearly not rele-
vant, with a low threshold for including within the review.
Two reviewers screened the abstracts of all studies for inclu-
sion. Full text was obtained for all potential articles of interest.
All full texts were assessed for eligibility by two reviewers.
Disagreements were resolved by consensus or referred to a
third reviewer (RP).
Quality assessment and data extraction
The quality of all guidelines was assessed using the AGREE II
criteria by two researchers [8]. General data were collected for
each included guideline, including producing body, funding
source and the intended audience. The recommendations of
Table 1 The AGREE II tool
items and domains [8] Domain Items
Scope and purpose 1. The overall objective(s) of the guideline is (are) specifically described.
2. The health question(s) covered by the guideline is (are) specifically described.
3. The population (patients, public, etc.) to whom the guideline is meant to apply is
specifically described.
Stakeholder
involvement
4. The guideline development group includes individuals from all relevant professional
groups.
5. The views and preferences of the target population (patients, public, etc.) have been
sought.
6. The target users of the guideline are clearly defined.
Rigour of
development
7. Systematic methods were used to search for evidence.
8. The criteria for selecting the evidence are clearly described.
9. The strengths and limitations of the body of evidence are clearly described.
10. The methods for formulating the recommendations are clearly described.
11. The health benefits, side effects, and risks have been considered in formulating the
recommendations.
12. There is an explicit link between the recommendations and the supporting evidence.
13. The guideline has been externally reviewed by experts prior to its publication.
14. A procedure for updating the guideline is provided.
Clarity of
presentation
15. The recommendations are specific and unambiguous.
16. The different options for management of the condition or health issue are clearly
presented.
17. Key recommendations are easily identifiable.
Applicability 18. The guideline describes facilitators and barriers to its application.
19. The guideline provides advice and/or tools on how the recommendations can be put
into practice.
20. The potential resource implications of applying the recommendations have been
considered.
21. The guideline presents monitoring and/or auditing criteria.
Editorial
independence
22. The views of the funding body have not influenced the content of the guideline.
23. Competing interests of guideline development group members have been recorded
and addressed.
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each guideline were extracted and then the data iteratively
analysed. Key elements of inconsistency were explored, relat-
ing these areas to quality of development, health care system
within which the guideline was developed and the evidence
from which the recommendation was derived. The rigour of
development domain was considered the key descriptor of
quality, as this domain assesses the description of the methods
of searching, selecting and combining evidence in the creation
of the guidelines. Guidelines with an AGREE II development
score of GOOD (defined as a scaled domain score of 65 % on
4 or more domains, which had to include ‘Rigour of
Development’ and ‘Clarity of Presentation’) were examined
to establish whether this group provide different guidance to
those with poorer development scores.
Results
Guideline details
Initial searches, including 930 entries (after removal of
duplicates), were sifted for titles which were clearly not
relevant. Eighty-four abstracts were assessed in detail,
with 32 full text articles retrieved and one additional
guideline identified after contacting experts. Fourteen of
these were included in the final analysis (see Fig. 1).
Five further guidelines were identified by the updated
search in September 2015, bringing the total number of
included guidelines to 19. Information on excluded
guidelines is given in Online Resource 2, and general
information for each included guideline in Online
Resource 3.
Ten guidelines provided recommendations on prophy-
laxis against fungal disease [9–18], five presented recom-
mendations for empirical treatment [10, 11, 15, 16, 19] and
13 gave guidance on the management of specific fungal
infections [9, 11, 15, 17, 19–27]. The majority guidelines
come from North America and Europe, with one each from
Australasia and Asia.
Quality assessment
Individual AGREE II domain scores for each guideline along
with median and interquartile ranges for each domain are giv-
en in Online Resource 4. The scores for the rigour of devel-
opment domain ranged from 11 to 92 % with a median of
53 % (interquartile range 32–69 %). This is somewhat poorer
than the rigour of development seen in guidelines in other
areas of Paediatric Haematology and Oncology [28]. In other
domains, the scope and purpose and clarity of presentation
domains generally scored highly, with stakeholder involve-
ment and editorial independence domains being much more
variable. The applicability domain generally scored poorly,
with minimal consideration given to how to implement their
recommendations into practice.
Only two guidelines received an AGREE II development
score of GOOD [13, 24]. One of these was a focused guideline
on confirmed sporotrichosis and therefore contributes little to
the other aspects of this review [24]. The other GOOD guide-
line was the C17 guideline which addresses primary antifungal
prophylaxis in children with cancer [13]. Generally, the other,
poorer quality guidelines gave recommendations that are con-
sistent with the C17 work. However, there was disagreement
over the use of prophylaxis in early phases of ALL treatment,
where the C17 guideline did not recommend prophylaxis use,
in contrast to other included guidelines.
Analysis
The main recommendations from the guidelines are
summarised in Table 2, with the recommendations from
GOOD quality guidelines highlighted in italics.
Prophylaxis
Education about dietary and environmental risk factors for in-
vasive fungal disease was advised by two of the guidelines, and
84 references idenfied aer 
Title screening 
14 Included in review
32 Full text arcles retrieved  
52 Excluded aer review of Abstract 
19 Excluded aer review of Full text
2 reviews of guidelines 
1 editorial 
1 not a clinical pracce 
guideline 
2 consensus statement only 
5 adult only guidelines  
2 duplicate/earlier versions of 
an included guideline 
5 in Spanish  
1 diagnosc only guideline 
1 Included aer contacng experts
5 Included aer updated search
19 Included in review
930 references idenfied by 
database searches (aer 
removal of duplicates)
846 Excluded aer review of Title 
Fig. 1 Flow diagram for guideline selection
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specific details of their recommendations included in each [12,
14]. Topical treatments (including nystatin and clotrimazole)
were not advised for the prevention of invasive fungal disease
in any guideline except the Taiwanese guideline [12, 15, 16].
The included guidelines which mentioned prophylaxis were
clear that all allogeneic transplant recipients should receive
antifungal prophylaxis during their neutropenia [9–15, 18].
Those guidelines that mentioned patients receiving autologous
stem cell return also advised prophylaxis for this group [9, 10,
12–16]. Similarly, many guidelines recommended prophylaxis
for those with AML and relapsed leukaemia; the other guide-
lines did not specifically comment on these groups [10–14].
Recommendations for prophylaxis in the early phases of treat-
ment for ALL, specifically in induction, were less clear, with
four guidelines recommending prophylaxis [9–11, 14] whilst
the C17 Council advised that it was not required. [13].
Fluconazole was recommended as anti-yeast prophylaxis
in all nine of the included guidelines which recommended a
Table 2 Summary of guideline
recommendations Recommendations
Prophylaxis
Primary prophylaxis
recipients
• Allogeneic HSCT—eight guidelines [9–15, 18]
• Autologous stem cell return—seven guidelines [9, 10, 12–16]
• AML and relapsed leukaemia—five guidelines [10–14]
• Early phases of ALL—four guidelines [9–11, 14]
• NOT early phases of ALL—one guideline [13]
Primary prophylaxis
drugs
• Fluconazole—nine guidelines [9–16, 18]
• Liposomal amphotericin B—four guidelines [10, 11, 14, 15]
• Itraconazole—six guidelines [10–12, 14, 15, 18]
• Posaconazole—seven guidelines [9–14, 18]
• Voriconazole—four guidelines [10–12, 18]
• Micafungin—four guidelines [10–12, 18]
• Caspofungin—one guideline [9]
Duration • Until neutrophil count recovery—eight guidelines [9–16]
• Day 0 to day 75 in allogeneic HSCT—two guidelines [10, 18]
• Until steroid dose <0.5 mg/kg/day of prednisolone—one guideline [14]
Empirical and pre-emptive therapy
Drugs advised • Liposomal amphotericin B—five guidelines [9–11, 15, 16, 19]
• Caspofungin—three guidelines [9, 11, 15]
• Itraconazole—two guidelines [9, 15]
• Voriconazole—two guidelines [9, 15]
• Fluconazole (when not used for prophylaxis)—three guidelines [9, 15, 19]
Initiation • Persistent febrile neutropenia, without a clear source, after 4 days of broad-
spectrum antibiotic therapy—two guidelines [11, 15]
Duration •Resolution of granulocytopenia in absence of suspected or documented IFD—one
guideline [11]
• Reassess and consider after 48–72 h—one guideline [15]
Specific therapies
Candida • Remove all central lines—five guidelines [9, 11, 19, 20, 25]
• Use fluconazole, an echinocandin or high-dose amphotericin B—five guidelines
[9, 11, 15, 19, 25]
• Duration—at least 14 days from last positive, or first negative, blood culture—
four guidelines [9, 11, 19, 25]
Invasive aspergillosis • Use voriconazole or high-dose liposomal amphotericin B—three guidelines [11,
15, 19]
• Echinocandins are an acceptable alternative—three guidelines [11, 15, 19]
• Duration dependent on response and immunological recovery—one guideline
[19]
Recommendations consistent with the C17 guidelines are in italics
HSCT haematopoietic stem cell transplant, AML acute myeloid leukaemia, ALL acute lymphoblastic lymphoma
Support Care Cancer
specific drug [9–16, 18]. Liposomal amphotericin B was
named as an appropriate alternative agent in four of these
guidelines [10, 11, 14, 15], itraconazole in six [10–12, 14, 15,
18], posaconazole in seven [9–14, 18], voriconazole in four
[10–12, 18], micafungin in four [10–12, 18] and caspofungin
in one [9]. Therapeutic drug monitoring when using
itraconazole was advised in three guidelines [10, 11, 18].
The duration of prophylaxis advised by included guidelines
universally recommended continuation until neutrophil count
recovery (to >1.0 × 109/L where specified) [9–16]. The
ESCMID and GITMO guidelines recommended prophylaxis
from day 0 to day 75 in allogeneic HSCT recipients [10, 18].
The SEIMC guidelines recommended continuation of antifun-
gal prophylaxis until the steroid dose was <0.5 mg/kg/day of
prednisolone [14].
Secondary prophylaxis is a term often used to describe ongo-
ing treatment or prophylaxis against further fungal infection fol-
lowing a previous episode of IFD. Two guidelines gave recom-
mendations about secondary prophylaxis. One recommended a
mould-activedrug,potentiallyvoriconazole, followingprevious
invasive aspergillosis; the other recommended ongoing treat-
ment until the patient was immunocompetent, but did not give
further guidance about this aspect of IFDmanagement [11, 12].
Empirical and pre-emptive therapy
Empirical treatment is that which is initiated when a physician
suspects IFD in a high-risk patient, in particular a child with
prolonged febrile neutropenia, but has no diagnostic evidence
for IFD, whilst pre-emptive treatment describes the use of
antifungal agents in patients with probable IFD whilst
awaiting diagnostic results, as per EORTC/MSG definitions
[29]. The guidelines included in this review generally provid-
ed empirical treatment recommendations which are described
in this appraisal. The ECIL-4 guidelines recommended that
pre-emptive treatment strategies may be appropriate for cer-
tain children in facilities where rapid results of diagnostic tests
are available; no other guideline provided guidance on pre-
emptive treatment [11].
Liposomal amphotericin B was recommended in all five
guidelines giving empirical therapy recommendations [9–11,
15, 16, 19]. This was based on equal efficacy, reduced number
of breakthrough infections, reduced infusion related toxicity
and reduced nephrotoxicity compared with other agents [16,
19]. Caspofungin was given as an acceptable alternative in the
IDSA, ECIL-4 and Taiwanese guidelines [9, 11, 15].
Itraconazole or voriconazole were stated as appropriate alter-
natives by two guidelines [9, 15]. Where fluconazole prophy-
laxis had not been administered, the IDSA, Australasian and
Taiwanese guidelines recommended that fluconazole could be
used for empirical treatment [9, 15, 19].
Where indications for initiating treatment were given, these
advised the introduction of empirical antifungals if there is
persistent febrile neutropenia, without a clear source, after
4 days of treatment with broad-spectrum antibacterial therapy
[11, 15]. There were few recommendations about when to stop
empirical antifungal therapy. ECIL-4 guidelines suggested on
Bresolution of granulocytopenia in the absence of suspected or
documented IFD^ [11] whilst the Taiwanese guidelines advised
reassessment and possible discontinuation after 48–72 h [15].
Specific therapy
Invasive candida infection All guidelines covering invasive
candida infections recommended the removal of all central
lines, if possible [9, 11, 19, 20, 25]. Fluconazole, an
echinocandin (usually caspofungin) or high-dose
amphotericin B (3–5 mg/kg/day) was recommended for use
in children in many of the included guidelines—dependent on
previous antifungal exposure [9, 11, 15, 19, 25]. The included
guidelines recommended that the duration of therapy in un-
complicated candidiasis be at least 14 days from either the last
positive or the first negative blood culture [9, 11, 19, 25].
Invasive aspergillosis and other mould infections All guide-
lines covering invasive aspergillosis advised the use of
voriconazole or high-dose liposomal amphotericin B (at least
3 mg/kg/day) as first-line therapy [11, 15, 19]. Echinocandins
such as caspofungin were considered as acceptable alternatives
[11, 15, 19]. Only one guideline gave recommendations on
treatment duration; the Australasian guideline recommended
consideration of response and immunological recovery [19].
Other confirmed invasive fungal diseases Various other
guidelines provided recommendations for the appropriate an-
tifungals in other invasive fungal diseases, including crypto-
coccosis, blastomycosis, histoplasmosis, sporotrichosis,
mucormycosis, black fungi and rare invasive yeasts [11, 15,
17, 21–24, 26, 27].
Discussion
This review has appraised 19 guidelines produced by various
international groups on the management of fungal infection in
paediatric haematology and oncology. The quality of the in-
cluded guidelines was variable. Only two guidelines met the
pre-study definition of GOOD quality on the AGREE II as-
sessment. There are many broad themes and recommenda-
tions that were consistent within the included guidelines
though the specific details were, at times, contrasting. The
quality of the guidelines did not dramatically impact on the
recommendations given, except in relation to prophylaxis in
the early stages of ALL treatment.
The guidelines gave clear and concise recommendations
about prophylaxis in the paediatric haematology and oncology
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setting with a substantial degree of concordance. Few guide-
lines drew attention to the fact that fluconazole does not pro-
vide cover against mould infection, and even fewer identified
a need for environmental assessment for risk of mould infec-
tion. However, the use of itraconazole or posaconazole was
advised in the majority of guidelines discussing prophylaxis
and these agents would provide good mould cover in a high-
risk group [9–15, 18].
In respect to empirical treatment, the guidance was much
less precise, and there were few recommendations about when
to stop treatment that was started for persistent fever. For pre-
emptive treatment, we understand that further primary re-
search is needed to identify whether this approach is appro-
priate within paediatric services.
The main strength of this work lies in the systematic
searches for guidelines and the use of a structured appraisal
tool to assess each guideline individually. This brings many of
the strengths associated with systematic reviewing including
explicitly demonstrating review methodology, identifying a
breadth of research, reaching a clear understanding of the cur-
rent knowledge, and a reduction in the bias involved in
selecting included results. Furthermore, systematic searching
and appraisal allows for identification of key areas for further
research and development.
There is such a wide range in the quality of CPGs in
this review that the review itself might be unseated by
this feature. The guidelines generally have poorer qual-
ity rigour of development than was prospectively decid-
ed to be good and typically did not provide clear and
detailed descriptions of their methodology. In addition
to this, through limiting the review to English language
guidelines, we may have missed CPGs in other lan-
guages, which may be of better quality than those in-
cluded. The use of the ‘Guideline’ filter in MEDLINE
may also have limited the search as it relies on guide-
lines being indexed appropriately. The impact of this
limitation on the review is likely to be minimal given
the extent of searching other sources alongside
MEDLINE.
Taking into account these flaws, due to the consistency in
the conclusions reached, we have been able to provide a clear
summary of the current recommendations for antifungal ther-
apy in paediatric haematology and oncology. We have been
able to identify key similarities across studies of both good
and poor quality and have also demonstrated repeated areas
for further primary research. In particular, we have been able
to explore the current guideline literature regarding antifungal
prophylaxis in children.
The review of these guidelines has identified a series of
guideline gaps in which key clinical questions are poorly ad-
dressed and require further recommendations to be made.
These include the decision to discontinue empirical antifungal
treatment in children, the relative benefits of empiric and pre-
emptive strategies and a clearer definition of risk strata which
are agreed between guideline groups. Clarity in these areas
could provide substantial patient and healthcare service bene-
fits. Further work is also required to determine the most ap-
propriate secondary prophylaxis for children and young peo-
ple who have already been treated for a probable or proven
invasive fungal disease. Furthermore, although not within the
scope of this work, a review of guidelines or research sur-
rounding the investigation of possible IFD, through imaging
and laboratory investigations, may also be relevant to the pae-
diatric haematology and oncology community.
Through demonstrating the areas where the current level of
guidance is poor, we hope to inform further research such that
future CPGs can progress from the current stance. In the
meantime, paediatric haematology and oncology teams
should work towards implementing the guidance where this
proves to be similar across the current CPGs, specifically in
regards to prophylactic therapy for children and young people
at risk of fungal infections.
Future iterations of guidelines should consider work-
ing to published guideline production methodologies
[30] and sharing summaries of evidence appraisal to
reduce duplication of effort, within an international net-
work such as the International Paediatric Oncology
Guidelines in Supportive Care Network, improving the
quality and efficiency of future clinical practice guide-
lines in this area. Guideline developers should consider
reference to the AGREE II tool as a checklist for es-
sential items to consider when writing their reports, pay-
ing particular attention to the systematic methods
discussed in the rigour of development domain. Future
guideline developers should also consider how to in-
crease the applicability of the recommendations they
produce.
Conclusions
Within this review we have critically appraised and analysed
current published guidelines on antifungal therapy for paedi-
atric haematology and oncology. The recommendations var-
ied in regards to the strength of evidence behind them. Despite
this, there were few areas of discrepancy. In areas where mul-
tiple guidelines exist, it may be sensible to use these tech-
niques to assess the current discourse so as to focus future
research and prevent replication of prior works.
There are many areas where the recommendations were
clear about appropriate practice but further clarity is required,
particularly the decision to discontinue empirical antifungal
treatment in children, the relative benefits of empiric and
pre-emptive strategies and a clearer definition of risk strata.
We recommend the use of guideline production aids for future
authors.
Support Care Cancer
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